About the GATHER2 Clinical Trial
GATHER2 is a phase 3 trial testing a potential treatment known as Zimura® (avacincaptad pegol).
A phase 3 trial is the final phase of testing typically required for a treatment to be approved by the US Food and Drug Administration (FDA).
The trial doctors want to find out if Zimura® can help slow down the progression of geographic atrophy (GA).
The trial doctors will also evaluate potential side effects of Zimura®.
GATHER2 was designed based on the results of the completed GATHER1 phase 3 clinical trial.
You may want to talk to your eye doctor to learn more about the GATHER2 Clinical Trial.
Learn About Clinical Trials.
Trial participants will be randomly placed into two groups.
Group 1 participants will receive Zimura® 2 mg eye injections once a month.
Group 2 participants will receive a sham procedure meant to simulate an injection once a month.
The sham group will not get an injection into the eye.
At the beginning of Year 2, those in the Zimura® group will be randomly placed into two new groups.
Some participants will continue to receive Zimura® once a month.
Some participants will receive Zimura® once every other month.
Patients in the sham group will remain in the sham group.
Two eye doctors will monitor you throughout the trial on a monthly basis.
The diagram shows how participants will be grouped.
ZIMURA® IS AN INVESTIGATIONAL PRODUCT AND HAS NOT BEEN APPROVED BY THE FDA. SAFETY AND EFFICACY OF ZIMURA® FOR AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY HAVE NOT BEEN ESTABLISHED. PLEASE SPEAK TO YOUR DOCTOR ABOUT PARTICIPATING IN THIS TRIAL.
Zimura® (avacincaptad pegol) is a registered trademark of IVERIC bio, Inc.